Search clinical trials for: Insulin Glulisine (HMR1964)

Total 2789 results

Sanofi

Completed

12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.

Diabetes, Type I

Germany, Netherlands, France
Sanofi

Completed

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

Diabetes Mellitus, Type 1

Belarus
Sanofi

Completed

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day (SeLan)

Diabetes Mellitus, Type 2

Israel
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Type 2 Diabetes Mellitus

India
Sanofi

Completed

Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients (VARIABILITE)

Diabetes Mellitus, Type 1

France
IKFE Institute for Clinical Research and Development

Completed

Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers

Diabetes

Germany
Sanofi

Completed

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

Type1 Diabetes Mellitus

Germany
Sanofi

Completed

Insulin Glulisine in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Insulin Glulisine in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Sanofi

Completed

Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus (SCALE)

Diabetes Mellitus

Egypt
Sanofi

Completed

APIDRA Registration Study

Diabetes Mellitus, Type 1

Kazakhstan
Sanofi

Completed

Insulin Glulisine in Diabetes Mellitus, Type 2 (GINGER)

Diabetes Mellitus, Type 2

France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
Sanofi

Terminated

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Diabetes Mellitus, Type 2

United States
Sanofi

Terminated

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction (INTENSIVE)

AMI

Canada, Brazil, United States, Argentina, Mexico
Sanofi

Completed

Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2)

Type 2 Diabetes

United States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Sanofi

Terminated

Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Diabetes Mellitus, Type 2

Brazil
Sanofi

Completed

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study (GLANS)

Diabetes Mellitus, Type 1

Bahrain, Kuwait, Qatar, United Arab Emirates
Sanofi

Completed

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Diabetes Mellitus

China
Sanofi

Completed

Insulin Glulisine in Healthy Lean and Obese Subjects

Diabetes Mellitus
HealthPartners Institute

Completed

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

Down Syndrome

United States
HaEmek Medical Center, Israel

Completed

Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

Diabetes Mellitus Type 2
Sanofi

Completed

Self Titration With Apidra to Reach Target Study (START)

Diabetes Mellitus, Type 2

Canada
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Sanofi

Completed

Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Sanofi

Completed

Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Sanofi

Completed

Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Sanofi

Completed

Apidra Children & Adolescents Study

Diabetes Mellitus, Type 1

Russian Federation
Medical University of Warsaw

Completed

Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal

Diabetes Mellitus, Type 1

Poland
Medical University of Warsaw

Not yet recruiting

The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.

Diabetes Mellitus, Type 1
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Sanofi

Completed

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients (LanScape)

Diabetes Mellitus, Type 2

Australia, United Kingdom
Sanofi

Completed

Insulin Glargine "All to Target" Trial

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy (OSIRIS)

Diabetes Mellitus, Type 2

France, Korea, Republic of, Russian Federation, Spain, Italy, Belgium, Germany, Hungary, Ireland, Mexico, Poland, Taiwan, Turkey, Netherlands, Greece, Lithuania, Sweden, United Kingdom
Medical University of Warsaw

Completed

Normal Versus Dual Wave Insulin Bolus for High-protein Food

Type 1 Diabetes

Poland
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Spectrum Health Hospitals
Helen DeVos Children's Hospital

Completed

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

Type 1 Diabetes Mellitus

United States
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Emory University

Completed

Glargine U300 Hospital Trial

Type 2 Diabetes

United States
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia
Carl T. Hayden VA Medical Center
Sanofi

Completed

Comparison of Apidra to Regular Insulin in Hospitalized Patients (Apidra)

Diabetes Mellitus, Type II

United States
Guillermo Umpierrez, MD
Medical University of South Carolina; Sanofi; Texas A&M University

Completed

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) (Basal-Plus)

Hyperglycemia | Type 2 Diabetes

United States
Sanofi

Completed

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. (DINAMO)

Diabetes Mellitus, Type 2

Brazil
The Royal Bournemouth Hospital
Sanofi

Terminated

Insulin Therapy in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Hyperglycemia | Chronic Obstructive Pulmonary Disease

United Kingdom
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
Sanofi

Completed

Insulin Glulisine in Type 2 Diabetic Patients (Basal Plus)

Diabetes Mellitus, Type 2

Russian Federation, United States, United Kingdom

3

Subscribe